JP6266617B2 - 置換ヘテロアゼピノン - Google Patents
置換ヘテロアゼピノン Download PDFInfo
- Publication number
- JP6266617B2 JP6266617B2 JP2015525858A JP2015525858A JP6266617B2 JP 6266617 B2 JP6266617 B2 JP 6266617B2 JP 2015525858 A JP2015525858 A JP 2015525858A JP 2015525858 A JP2015525858 A JP 2015525858A JP 6266617 B2 JP6266617 B2 JP 6266617B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- oxo
- methylamino
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OCMHPPPTGLZOBJ-UHFFFAOYSA-N Cc(c(c1c2)ccc2F)n[n]1-c1ccccc1C#N Chemical compound Cc(c(c1c2)ccc2F)n[n]1-c1ccccc1C#N OCMHPPPTGLZOBJ-UHFFFAOYSA-N 0.000 description 2
- BDZNAVXAAXPFMT-UHFFFAOYSA-N Nc(c1ccccc11)c(C#N)[n]1-c1ccccc1C#N Chemical compound Nc(c1ccccc11)c(C#N)[n]1-c1ccccc1C#N BDZNAVXAAXPFMT-UHFFFAOYSA-N 0.000 description 2
- BGTYTVSQUPYHAC-UHFFFAOYSA-N Nc(c1ccccc11)n[n]1-c1ccccc1C#N Chemical compound Nc(c1ccccc11)n[n]1-c1ccccc1C#N BGTYTVSQUPYHAC-UHFFFAOYSA-N 0.000 description 2
- STPHEUUFTOGKNY-JTQLQIEISA-N CC(C)(C)OC(N[C@@H](COc(cccc1)c1N1)C1=O)=O Chemical compound CC(C)(C)OC(N[C@@H](COc(cccc1)c1N1)C1=O)=O STPHEUUFTOGKNY-JTQLQIEISA-N 0.000 description 1
- QVYDCSLVYRFRCL-UHFFFAOYSA-N CCNC(c(cc1)cc(C#N)c1-[n]1nc(C)c2c1cccc2)=O Chemical compound CCNC(c(cc1)cc(C#N)c1-[n]1nc(C)c2c1cccc2)=O QVYDCSLVYRFRCL-UHFFFAOYSA-N 0.000 description 1
- HMVPFYXQYROUBV-UHFFFAOYSA-N CCNC(c(cc1C#N)ccc1-[n](c1c2cccc1)nc2N)=O Chemical compound CCNC(c(cc1C#N)ccc1-[n](c1c2cccc1)nc2N)=O HMVPFYXQYROUBV-UHFFFAOYSA-N 0.000 description 1
- OICHJWNMJNGMBK-SGHJWQDXSA-N CCNC(c(cc1C#N)ccc1-[n]1ncc2c(CN(c(cccc3)c3O[C@@H](C)[C@@H]3NC([C@H](C)NC)=O)C3=O)cccc12)=O Chemical compound CCNC(c(cc1C#N)ccc1-[n]1ncc2c(CN(c(cccc3)c3O[C@@H](C)[C@@H]3NC([C@H](C)NC)=O)C3=O)cccc12)=O OICHJWNMJNGMBK-SGHJWQDXSA-N 0.000 description 1
- YICGYMHMOGVPNK-UHFFFAOYSA-N CC[n]1c2cccc(CO)c2cc1 Chemical compound CC[n]1c2cccc(CO)c2cc1 YICGYMHMOGVPNK-UHFFFAOYSA-N 0.000 description 1
- FTLFWECWQDBFNU-IDISGSTGSA-N C[C@@H](C(N[C@@H](COc(c(C(N1CCN(CCCO)CC1)=O)ccc1)c1N1Cc(c2ccccc22)ccc2Br)C1=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](COc(c(C(N1CCN(CCCO)CC1)=O)ccc1)c1N1Cc(c2ccccc22)ccc2Br)C1=O)=O)NC FTLFWECWQDBFNU-IDISGSTGSA-N 0.000 description 1
- VLWUWJOMYZATBO-FNZWTVRRSA-N C[C@@H](C(N[C@@H](COc(c(N1Cc(c2ccccc22)ccc2Br)ccc2)c2C(N2CCN(CCO)CC2)=O)C1=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](COc(c(N1Cc(c2ccccc22)ccc2Br)ccc2)c2C(N2CCN(CCO)CC2)=O)C1=O)=O)NC VLWUWJOMYZATBO-FNZWTVRRSA-N 0.000 description 1
- FXWNXUAVASQHNP-YWZLYKJASA-N C[C@@H](C(N[C@@H](COc(cccc1)c1N1Cc(c(c(cc2)c3)ccc3C(O)=O)c2OC)C1=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](COc(cccc1)c1N1Cc(c(c(cc2)c3)ccc3C(O)=O)c2OC)C1=O)=O)NC FXWNXUAVASQHNP-YWZLYKJASA-N 0.000 description 1
- PLXKZOVCTWRTPJ-CYFREDJKSA-N C[C@@H](C(N[C@@H](CSc(c(N1Cc2cccc3c2cccc3)ccc2)c2NC(COCCOC)=O)C1=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](CSc(c(N1Cc2cccc3c2cccc3)ccc2)c2NC(COCCOC)=O)C1=O)=O)NC PLXKZOVCTWRTPJ-CYFREDJKSA-N 0.000 description 1
- WQQQEYXDLUUDKD-UHFFFAOYSA-N Cc(c(cccc1)c1[n]1-c(cccc2)c2C#N)c1Cl Chemical compound Cc(c(cccc1)c1[n]1-c(cccc2)c2C#N)c1Cl WQQQEYXDLUUDKD-UHFFFAOYSA-N 0.000 description 1
- YWDNNAUHSNSLIC-UHFFFAOYSA-N NC(C1(CCCCC1)Oc(cccc1)c1N1)C1=O Chemical compound NC(C1(CCCCC1)Oc(cccc1)c1N1)C1=O YWDNNAUHSNSLIC-UHFFFAOYSA-N 0.000 description 1
- ZLJQJHZJRQALJX-UHFFFAOYSA-N NC(C1(CCOCC1)Oc(c(N1)ccc2)c2F)C1=O Chemical compound NC(C1(CCOCC1)Oc(c(N1)ccc2)c2F)C1=O ZLJQJHZJRQALJX-UHFFFAOYSA-N 0.000 description 1
- UTFARTJBEDWGPV-UHFFFAOYSA-N Nc(c(cccc1)c1[n]1-c2ccccc2C#N)c1Cl Chemical compound Nc(c(cccc1)c1[n]1-c2ccccc2C#N)c1Cl UTFARTJBEDWGPV-UHFFFAOYSA-N 0.000 description 1
- QUTILIHOEOJSCD-UHFFFAOYSA-N [O-][N+](c(cccc1Cc2ccccc2)c1F)=O Chemical compound [O-][N+](c(cccc1Cc2ccccc2)c1F)=O QUTILIHOEOJSCD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681337P | 2012-08-09 | 2012-08-09 | |
| US61/681,337 | 2012-08-09 | ||
| PCT/EP2013/066431 WO2014023708A1 (en) | 2012-08-09 | 2013-08-06 | Substituted hetero-azepinones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528821A JP2015528821A (ja) | 2015-10-01 |
| JP2015528821A5 JP2015528821A5 (enExample) | 2017-12-21 |
| JP6266617B2 true JP6266617B2 (ja) | 2018-01-24 |
Family
ID=48951449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525858A Expired - Fee Related JP6266617B2 (ja) | 2012-08-09 | 2013-08-06 | 置換ヘテロアゼピノン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9394263B2 (enExample) |
| EP (1) | EP2882725A1 (enExample) |
| JP (1) | JP6266617B2 (enExample) |
| KR (1) | KR20150041647A (enExample) |
| CN (1) | CN104470905B (enExample) |
| BR (1) | BR112015001830A2 (enExample) |
| CA (1) | CA2877048A1 (enExample) |
| MX (1) | MX2015001720A (enExample) |
| RU (1) | RU2015105561A (enExample) |
| WO (1) | WO2014023708A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015004547A8 (pt) * | 2012-09-19 | 2018-01-23 | Hoffmann La Roche | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| EP3760625B1 (en) | 2015-07-02 | 2024-03-27 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| CN106467521A (zh) * | 2015-08-14 | 2017-03-01 | 陈志龙 | 一类双苯并咪唑吲哚衍生物的两种制备方法 |
| CN106467515B (zh) * | 2015-08-18 | 2019-09-24 | 宁波洞密生物科技有限公司 | 一类6-吡啶苯并咪唑吲哚衍生物及其制备方法与医药领域的应用 |
| AU2017213628B2 (en) | 2016-02-05 | 2021-07-29 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| US20220402935A1 (en) | 2019-07-31 | 2022-12-22 | Fimecs, Inc. | Heterocyclic compound |
| CR20230263A (es) | 2020-12-17 | 2023-08-21 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos |
| AU2022221124A1 (en) * | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| CN117980294A (zh) * | 2021-09-01 | 2024-05-03 | 海南先声再明医药股份有限公司 | 泛素特异性蛋白酶1（usp1）抑制剂 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| WO2023150790A2 (en) * | 2022-02-07 | 2023-08-10 | The Wistar Institute Of Anatomy And Biology | Novel and highly selective sars-cov-2 mpro inhibitors |
| TW202417439A (zh) * | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
| MA71728A (fr) * | 2022-08-11 | 2025-05-30 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydrothiazépine |
| JP2025526727A (ja) * | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| WO2024033458A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
| CN119930413B (zh) * | 2025-04-10 | 2025-07-22 | 山东辉璟生物医药科技有限公司 | 一种萘丁美酮-d3的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| CN101115730A (zh) * | 2004-12-14 | 2008-01-30 | 阿斯利康(瑞典)有限公司 | 新分子探针 |
| AU2006255084A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| WO2007101347A1 (en) * | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US20090054398A1 (en) * | 2006-03-10 | 2009-02-26 | Astrazeneca Ab | Chemical compounds |
| AU2008219723A1 (en) * | 2007-02-28 | 2008-09-04 | Merck Sharp & Dohme Corp. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
-
2013
- 2013-08-06 MX MX2015001720A patent/MX2015001720A/es unknown
- 2013-08-06 EP EP13747659.4A patent/EP2882725A1/en not_active Withdrawn
- 2013-08-06 CA CA2877048A patent/CA2877048A1/en not_active Abandoned
- 2013-08-06 BR BR112015001830A patent/BR112015001830A2/pt not_active IP Right Cessation
- 2013-08-06 US US14/418,383 patent/US9394263B2/en not_active Expired - Fee Related
- 2013-08-06 KR KR20157005929A patent/KR20150041647A/ko not_active Withdrawn
- 2013-08-06 CN CN201380035993.XA patent/CN104470905B/zh not_active Expired - Fee Related
- 2013-08-06 RU RU2015105561A patent/RU2015105561A/ru not_active Application Discontinuation
- 2013-08-06 WO PCT/EP2013/066431 patent/WO2014023708A1/en not_active Ceased
- 2013-08-06 JP JP2015525858A patent/JP6266617B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015001720A (es) | 2015-04-14 |
| BR112015001830A2 (pt) | 2017-07-04 |
| KR20150041647A (ko) | 2015-04-16 |
| WO2014023708A1 (en) | 2014-02-13 |
| CN104470905B (zh) | 2017-09-12 |
| HK1206740A1 (en) | 2016-01-15 |
| CN104470905A (zh) | 2015-03-25 |
| EP2882725A1 (en) | 2015-06-17 |
| US9394263B2 (en) | 2016-07-19 |
| RU2015105561A (ru) | 2016-09-27 |
| JP2015528821A (ja) | 2015-10-01 |
| US20150361059A1 (en) | 2015-12-17 |
| CA2877048A1 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6266617B2 (ja) | 置換ヘテロアゼピノン | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| JP7356450B2 (ja) | 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法 | |
| JP6302912B2 (ja) | ２−オキソ−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ［ｂ］ジアゼピン及びがんの治療におけるその使用 | |
| CN105517999B (zh) | Ido抑制剂 | |
| JP6680683B2 (ja) | テトラヒドロ−ベンゾジアゼピノン類 | |
| JP6313416B2 (ja) | Ｉｄｏ阻害剤 | |
| JP6141428B2 (ja) | 抗増殖性ベンゾ［ｂ］アゼピン−２−オン | |
| US20030232832A1 (en) | Pyrrolotriazinone compounds and their use to teat diseases | |
| CN105683167B (zh) | 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂 | |
| RS57545B1 (sr) | Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže | |
| CN105263927A (zh) | 新的抑制剂 | |
| CN111909157A (zh) | Ezh2抑制剂及其用途 | |
| CN102180826A (zh) | 含α氨基酸结构的组蛋白去乙酰化酶抑制剂及其用途 | |
| ES2866324T3 (es) | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria | |
| WO2021107125A1 (ja) | リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途 | |
| CN101522610A (zh) | 氨基醇的硝酸酯 | |
| US8993515B2 (en) | Peptidomimetics comprising N-amino cyclic urea residues and uses thereof | |
| KR20110085036A (ko) | 세포사멸 유도 활성을 갖는 이미다조피라진온 유도체 | |
| JP2009513510A (ja) | アスパラギン酸プロテアーゼ阻害活性を有する大環状化合物およびその医薬的使用 | |
| CN102321034B (zh) | 硫代苯二氮卓类化合物及其作为药物的用途 | |
| WO2023082052A1 (zh) | 环状2-氨基嘧啶类化合物及其用途 | |
| CN102010425A (zh) | 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用 | |
| WO2007067904A2 (en) | Peptide deformylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20171107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6266617 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |